The creation of next-generation medicines depends on the regulated activation of innate immunity. Important elements of vaccines and immunotherapies include adjuvants, or chemicals that modify the immune response. Emerging research supports the use of Immunostimulatory Adjuvants Market in treatments even if small compounds and biologics still dominate the adjuvant industry. By acting as pattern recognition receptor (PRR) agonists, these polymers can deliver and stabilise cargo while energising the immune system. Nevertheless, it is crucial to take into account any inadvertent activation of an immune response that results in unfavourable immunological-related events when developing polymers that activate the immune system. Here, we focus on polymer scaffolds that are biologically derived and synthetic, as well as polymer-adjuvant systems and stimuli-responsive polymers loaded with adjuvants, that can elicit an immune response.
